Maron BJ, Pelliccia A, Spirito P Cardiac disease in young trained athletes. Insights into methods for distinguishing athlete's heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy. . Although the studies had important differences in design and patient characteristicssomewhat uniquely in the complex world of clinical trials -they reported broadly consistent results. No significant differences in mortality or freedom from subsequent myocardial infarction were observed, although no individual trial was powered to examine these end-points in isolation. The PTCA strategy was limited by a greater need for repeat revascularization procedures (34% PTCA v 33% CABG in the first year of follow-up)'
61
, and less effective relief of anginal symptoms. These findings can perhaps be attributed to the less complete revascularization achieved with the percutaneous approach and the established problem of lesion restenosis.
A meta-analysis of the earlier trials has been published' 61 and these observations have now been extended to include the BARI data'
71
. The combined sample size of 5200 patients reveals a trend to increased mortality in the PTCA group that approaches normal levels of statistical significance (Risk Ratio 1-2, 95%C1 0-97-1-48).
It might appear, therefore, that CABG remains the treatment of choice in patients with advanced coronary disease but the interventional cardiologists still have much to offer. There may be cost advantage with PTCA' 81 and many patients appreciate the shorter initial hospital stay and reduced immediate procedural morbidity. Advances in techniques and equipment, particularly the use of coronary stents, have widened the scope and improved the results of PTCA. New trials are being planned which will examine whether the benefits of primary coronary stent implantation, established in isolated lesions' 9 ' 101 can be translated to the multivessel setting. Patients with multi-vessel disease will be randomized to CABG or PTCA supported by stent implantation. The 'Stent or Surgery' Trial (SoS) has a pragmatic design, employing a range of stents that will allow the operator to adopt a lesionspecific choice of implant. The BENESTENT III or ARTS trial is device-specific and will use new stent technology from Johnson & Johnson Interventional Systems.
Coronary artery disease is in the main a progressive condition and although intensive risk factor modification, particularly lipid lowering therapy, may have an impact in this area it is likely that many patients will, over time, manifest new atherosclerotic disease in native vessels and bypass conduits. The current trials have reported only a short follow-up period, sufficient to demonstrate the full effects of PTCA lesion restenosis but too short for the effects of new disease in bypass grafts to become clinically apparent. Patients with this pattern of disease are difficult to manage, and although PTCA can be used, patients often require repeat bypass grafting. Re-operation has a greater morbidity and mortality than the initial procedure and often threatens a patent and well functioning internal mammary conduit. Initial use of a PTCA-based strategy may allow surgery to be delayed or avoided, particularly in younger patients.
The results of the angiographic sub-study of the German Angioplasty Bypass Investigation Editorials 1141 (GABI) published in this issue may add additional weight to this argument'" 1 . The CABRI and EAST trials also included scheduled angiographic follow-up but neither study has yet published a detailed report on these data. The GABI findings support existing data in suggesting that the presence of a functioning bypass graft conduit may precipitate the occlusion of diseased, but previously patent, native vessels. This may have important implications for subsequent revascularization procedures. Native vessel PTCA can sometimes be used as an alternative to reoperation in a patient with established graft disease but, when a bypass conduit has precipitated early occlusion, the value of this approach will be limited as PTCA success rates with chronic occlusions remains low.
The investigators also report that patients managed initially with PTCA demonstrated an increased number of lesions of apparent moderate severity (18-3% of PTCA patients vs 7-5% of CABG patients). It is sometimes difficult to assess the functional significance and hence clinical relevance of this type of lesion, although no doubt their angiographic demonstration precipitated a number of repeat revascularization procedures, triggered by the so called 'occulo-dilate' reflex [12 l The period of scheduled angiographic follow-up in the CABRI and EAST trials was associated with a marked increase in the rates of re-intervention, despite protocol safeguards designed to prevent this. The real clinical impact of restenosis in the multi-vessel patient may not be quite as great, as suggested by the current evidence, and the impact of stent implantation on this problem remains to be assessed.
For the patient with symptomatic multi-vessel disease, the choice of management strategy is wide and personal preference will play an important part in the decision process. Medical therapy, with intensive risk factor and lifestyle modification, cannot be dismissed and may be ideal for patients with minimal symptoms and coronary disease that is not of prognostic significance. If revascularization is indicated the relative merits of surgery and PTCA will have to be weighed and, with involvement of interventionalist, surgeon and not least the patient, it is likely that the best course will become apparent.
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